#Position AA Comment NotAA 11 I The following $numberOfMutsIn{11I,32I,33F,47V,50V,54LM,74P,76V,84V,89V} of the 11 darunavir POWER/DUET study mutations were present: $listMutsIn{11I,32I,33F,47V,50V,54LM,74P,76V,84V,89V} (DeMeyer S et al, EHDRW 2008). 32 I The following $numberOfMutsIn{11I,32I,33F,47V,50V,54LM,74P,76V,84V,89V} of the 11 darunavir POWER/DUET study mutations were present: $listMutsIn{11I,32I,33F,47V,50V,54LM,74P,76V,84V,89V} (DeMeyer S et al, EHDRW 2008). 33 F The following $numberOfMutsIn{11I,32I,33F,47V,50V,54LM,74P,76V,84V,89V} of the 11 darunavir POWER/DUET study mutations were present: $listMutsIn{11I,32I,33F,47V,50V,54LM,74P,76V,84V,89V} (DeMeyer S et al, EHDRW 2008). 47 V The following $numberOfMutsIn{11I,32I,33F,47V,50V,54LM,74P,76V,84V,89V} of the 11 darunavir POWER/DUET study mutations were present: $listMutsIn{11I,32I,33F,47V,50V,54LM,74P,76V,84V,89V} (DeMeyer S et al, EHDRW 2008). 50 V The following $numberOfMutsIn{11I,32I,33F,47V,50V,54LM,74P,76V,84V,89V} of the 11 darunavir POWER/DUET study mutations were present: $listMutsIn{11I,32I,33F,47V,50V,54LM,74P,76V,84V,89V} (DeMeyer S et al, EHDRW 2008). 54 LM The following $numberOfMutsIn{11I,32I,33F,47V,50V,54LM,74P,76V,84V,89V} of the 11 darunavir POWER/DUET study mutations were present: $listMutsIn{11I,32I,33F,47V,50V,54LM,74P,76V,84V,89V} (DeMeyer S et al, EHDRW 2008). 74 P The following $numberOfMutsIn{11I,32I,33F,47V,50V,54LM,74P,76V,84V,89V} of the 11 darunavir POWER/DUET study mutations were present: $listMutsIn{11I,32I,33F,47V,50V,54LM,74P,76V,84V,89V} (DeMeyer S et al, EHDRW 2008). 76 V The following $numberOfMutsIn{11I,32I,33F,47V,50V,54LM,74P,76V,84V,89V} of the 11 darunavir POWER/DUET study mutations were present: $listMutsIn{11I,32I,33F,47V,50V,54LM,74P,76V,84V,89V} (DeMeyer S et al, EHDRW 2008). 84 V The following $numberOfMutsIn{11I,32I,33F,47V,50V,54LM,74P,76V,84V,89V} of the 11 darunavir POWER/DUET study mutations were present: $listMutsIn{11I,32I,33F,47V,50V,54LM,74P,76V,84V,89V} (DeMeyer S et al, EHDRW 2008). 89 V The following $numberOfMutsIn{11I,32I,33F,47V,50V,54LM,74P,76V,84V,89V} of the 11 darunavir POWER/DUET study mutations were present: $listMutsIn{11I,32I,33F,47V,50V,54LM,74P,76V,84V,89V} (DeMeyer S et al, EHDRW 2008). 47 V This sequence has $numberOfMutsIn{47V,54AMV,58E,74P,82LT,83D} major TPV-resistance mutations ($listMutsIn{47V,54AMV,58E,74P,82LT,83D}), $numberOfMutsIn{10V,36I,43T,46L,84V} minor TPV-resistance mutations ($listMutsIn{10V,36I,43T,46L,84V}), and $numberOfMutsIn{24I,50LV,54L,76V} mutations associated with increased TPV responsiveness ($listMutsIn{24I,50LV,54L,76V}). RESIST study (Baxter J et al J Virology 2006 and Scherer J et al EACS 2007). 54 AMV This sequence has $numberOfMutsIn{47V,54AMV,58E,74P,82LT,83D} major TPV-resistance mutations ($listMutsIn{47V,54AMV,58E,74P,82LT,83D}), $numberOfMutsIn{10V,36I,43T,46L,84V} minor TPV-resistance mutations ($listMutsIn{10V,36I,43T,46L,84V}), and $numberOfMutsIn{24I,50LV,54L,76V} mutations associated with increased TPV responsiveness ($listMutsIn{24I,50LV,54L,76V}). RESIST study (Baxter J et al J Virology 2006 and Scherer J et al EACS 2007). 58 E This sequence has $numberOfMutsIn{47V,54AMV,58E,74P,82LT,83D} major TPV-resistance mutations ($listMutsIn{47V,54AMV,58E,74P,82LT,83D}), $numberOfMutsIn{10V,36I,43T,46L,84V} minor TPV-resistance mutations ($listMutsIn{10V,36I,43T,46L,84V}), and $numberOfMutsIn{24I,50LV,54L,76V} mutations associated with increased TPV responsiveness ($listMutsIn{24I,50LV,54L,76V}). RESIST study (Baxter J et al J Virology 2006 and Scherer J et al EACS 2007). 74 P This sequence has $numberOfMutsIn{47V,54AMV,58E,74P,82LT,83D} major TPV-resistance mutations ($listMutsIn{47V,54AMV,58E,74P,82LT,83D}), $numberOfMutsIn{10V,36I,43T,46L,84V} minor TPV-resistance mutations ($listMutsIn{10V,36I,43T,46L,84V}), and $numberOfMutsIn{24I,50LV,54L,76V} mutations associated with increased TPV responsiveness ($listMutsIn{24I,50LV,54L,76V}). RESIST study (Baxter J et al J Virology 2006 and Scherer J et al EACS 2007). 82 LT This sequence has $numberOfMutsIn{47V,54AMV,58E,74P,82LT,83D} major TPV-resistance mutations ($listMutsIn{47V,54AMV,58E,74P,82LT,83D}), $numberOfMutsIn{10V,36I,43T,46L,84V} minor TPV-resistance mutations ($listMutsIn{10V,36I,43T,46L,84V}), and $numberOfMutsIn{24I,50LV,54L,76V} mutations associated with increased TPV responsiveness ($listMutsIn{24I,50LV,54L,76V}). RESIST study (Baxter J et al J Virology 2006 and Scherer J et al EACS 2007). 83 D This sequence has $numberOfMutsIn{47V,54AMV,58E,74P,82LT,83D} major TPV-resistance mutations ($listMutsIn{47V,54AMV,58E,74P,82LT,83D}), $numberOfMutsIn{10V,36I,43T,46L,84V} minor TPV-resistance mutations ($listMutsIn{10V,36I,43T,46L,84V}), and $numberOfMutsIn{24I,50LV,54L,76V} mutations associated with increased TPV responsiveness ($listMutsIn{24I,50LV,54L,76V}). RESIST study (Baxter J et al J Virology 2006 and Scherer J et al EACS 2007). 10 V This sequence has $numberOfMutsIn{47V,54AMV,58E,74P,82LT,83D} major TPV-resistance mutations ($listMutsIn{47V,54AMV,58E,74P,82LT,83D}), $numberOfMutsIn{10V,36I,43T,46L,84V} minor TPV-resistance mutations ($listMutsIn{10V,36I,43T,46L,84V}), and $numberOfMutsIn{24I,50LV,54L,76V} mutations associated with increased TPV responsiveness ($listMutsIn{24I,50LV,54L,76V}). RESIST study (Baxter J et al J Virology 2006 and Scherer J et al EACS 2007). 36 I This sequence has $numberOfMutsIn{47V,54AMV,58E,74P,82LT,83D} major TPV-resistance mutations ($listMutsIn{47V,54AMV,58E,74P,82LT,83D}), $numberOfMutsIn{10V,36I,43T,46L,84V} minor TPV-resistance mutations ($listMutsIn{10V,36I,43T,46L,84V}), and $numberOfMutsIn{24I,50LV,54L,76V} mutations associated with increased TPV responsiveness ($listMutsIn{24I,50LV,54L,76V}). RESIST study (Baxter J et al J Virology 2006 and Scherer J et al EACS 2007). 43 T This sequence has $numberOfMutsIn{47V,54AMV,58E,74P,82LT,83D} major TPV-resistance mutations ($listMutsIn{47V,54AMV,58E,74P,82LT,83D}), $numberOfMutsIn{10V,36I,43T,46L,84V} minor TPV-resistance mutations ($listMutsIn{10V,36I,43T,46L,84V}), and $numberOfMutsIn{24I,50LV,54L,76V} mutations associated with increased TPV responsiveness ($listMutsIn{24I,50LV,54L,76V}). RESIST study (Baxter J et al J Virology 2006 and Scherer J et al EACS 2007). 46 L This sequence has $numberOfMutsIn{47V,54AMV,58E,74P,82LT,83D} major TPV-resistance mutations ($listMutsIn{47V,54AMV,58E,74P,82LT,83D}), $numberOfMutsIn{10V,36I,43T,46L,84V} minor TPV-resistance mutations ($listMutsIn{10V,36I,43T,46L,84V}), and $numberOfMutsIn{24I,50LV,54L,76V} mutations associated with increased TPV responsiveness ($listMutsIn{24I,50LV,54L,76V}). RESIST study (Baxter J et al J Virology 2006 and Scherer J et al EACS 2007). 84 V This sequence has $numberOfMutsIn{47V,54AMV,58E,74P,82LT,83D} major TPV-resistance mutations ($listMutsIn{47V,54AMV,58E,74P,82LT,83D}), $numberOfMutsIn{10V,36I,43T,46L,84V} minor TPV-resistance mutations ($listMutsIn{10V,36I,43T,46L,84V}), and $numberOfMutsIn{24I,50LV,54L,76V} mutations associated with increased TPV responsiveness ($listMutsIn{24I,50LV,54L,76V}). RESIST study (Baxter J et al J Virology 2006 and Scherer J et al EACS 2007). 24 I This sequence has $numberOfMutsIn{47V,54AMV,58E,74P,82LT,83D} major TPV-resistance mutations ($listMutsIn{47V,54AMV,58E,74P,82LT,83D}), $numberOfMutsIn{10V,36I,43T,46L,84V} minor TPV-resistance mutations ($listMutsIn{10V,36I,43T,46L,84V}), and $numberOfMutsIn{24I,50LV,54L,76V} mutations associated with increased TPV responsiveness ($listMutsIn{24I,50LV,54L,76V}). RESIST study (Baxter J et al J Virology 2006 and Scherer J et al EACS 2007). 50 LV This sequence has $numberOfMutsIn{47V,54AMV,58E,74P,82LT,83D} major TPV-resistance mutations ($listMutsIn{47V,54AMV,58E,74P,82LT,83D}), $numberOfMutsIn{10V,36I,43T,46L,84V} minor TPV-resistance mutations ($listMutsIn{10V,36I,43T,46L,84V}), and $numberOfMutsIn{24I,50LV,54L,76V} mutations associated with increased TPV responsiveness ($listMutsIn{24I,50LV,54L,76V}). RESIST study (Baxter J et al J Virology 2006 and Scherer J et al EACS 2007). 54 L This sequence has $numberOfMutsIn{47V,54AMV,58E,74P,82LT,83D} major TPV-resistance mutations ($listMutsIn{47V,54AMV,58E,74P,82LT,83D}), $numberOfMutsIn{10V,36I,43T,46L,84V} minor TPV-resistance mutations ($listMutsIn{10V,36I,43T,46L,84V}), and $numberOfMutsIn{24I,50LV,54L,76V} mutations associated with increased TPV responsiveness ($listMutsIn{24I,50LV,54L,76V}). RESIST study (Baxter J et al J Virology 2006 and Scherer J et al EACS 2007). 76 V This sequence has $numberOfMutsIn{47V,54AMV,58E,74P,82LT,83D} major TPV-resistance mutations ($listMutsIn{47V,54AMV,58E,74P,82LT,83D}), $numberOfMutsIn{10V,36I,43T,46L,84V} minor TPV-resistance mutations ($listMutsIn{10V,36I,43T,46L,84V}), and $numberOfMutsIn{24I,50LV,54L,76V} mutations associated with increased TPV responsiveness ($listMutsIn{24I,50LV,54L,76V}). RESIST study (Baxter J et al J Virology 2006 and Scherer J et al EACS 2007). 10 IVFRY L10I/V/F/R are associated with resistance to each of the PIs when present with other mutations. L10I/V occur commonly in 5-10% of untreated persons. L10FRY are nonpolymorphic. 11 I V11I is a nonpolymorphic accessory mutation weakly associated with PI therapy. It is one of the 11 mutations associated with decreased response to DRV in the POWER trials. 13 V I13V is a common polymorphism that is slightly more common in treated compared with untreated subtype B isolates. In subtypes A, AE, AG, and G it is the consensus residue. I13V was weakly associated with decreased virological response to TPV in the RESIST trials. 16 EA G16E is a highly polymorphic mutation occurring in 2% to 20% of viruses depending on subtype. It may be weakly associated with ATV therapy and response. 20 RMIVT K20R/M/I/T are weakly associated with resistance to each of the PIs when present with other mutations. Many variants at this position occur commonly in non-subtype B viruses. 23 I L23I is a rare substrate cleft mutation that causes low-level resistance to NFV. 24 I L24I is associated with reduced susceptibility to IDV and possibly RTV, LPV, SQV, and ATV when present with other mutations. 24 F L24F is a rare mutation at this position; its phenotypic effect is not known. 30 N D30N causes intermediate resistance to NFV. 32 I V32I is a substrate cleft mutation that reduces susceptibility to IDV, RTV, FPV, LPV, TPV, and DRV. 33 F L33F are selected by FPV, DRV, LPV, ATV, and TPV, and slightly contribute resistance to these drugs. 33 I L33F are selected by FPV, DRV, LPV, ATV, and TPV, and slightly contribute resistance to these drugs. L33I is less common than L33F but may have a similar effect. 33 V L33V is a polymorphism that does not appear to be related to PI therapy or drug resistance. 35 G E35G is a nonpolymorphic mutation that is slightly more common in viruses from PI-treated (particularly NFV-treated) compared with untreated persons. It was weakly associated a decreased virological response to TPV in the RESIST trials. 36 IVLT M36I/V are weakly associated with PI resistance when present with other mutations. M36I occurs commonly in certain non-subtype B viruses. M36L/T are rare variants of uncertain significance. 43 T K43T is a nonpolymorphic mutation that is significantly more common in viruses from PI-treated compared with untreated persons. It was weakly associated with a decreased virological response to TPV in the RESIST trials. 46 IL M46I/L decreases susceptibility to IDV, NFV, FPV, LPV, ATV, TPV, and possibly SQV and DRV when present with other mutations. 46 V M46I/L decreases susceptibility to IDV, NFV, FPV, LPV, ATV, TPV, and possibly SQV and DRV when present with other mutations. M46V is a rare mutation at this position of uncertain significance. 47 V I47V decrease susceptibility to FPV, ATV, IDV, LPV, TPV, and DRV. 47 A I47A usually occurs in combination with V32I and in this setting causes high-level LPV and FPV resistance and probably intermediate DRV resistance. 48 V G48V causes high-level SQV resistance, intermediate ATV and NFV resistance, and low-level IDV and LPV resistance. 48 M G48M causes high-level SQV resistance and intermediate resistance to NFV, ATV, IDV, and NFV. 50 L I50L causes intermediate-to-high level resistance to ATV and hypersusceptibility to the remaining PIs. 50 V I50V causes intermediate-to-high-level resistance to FPV, intermediate resistance to LPV and DRV, and increased susceptibility to TPV. 53 LY F53L occurs only in isolates from treated patients nearly always in combinations with other PI-resistance mutations. It is associated with decreased susceptibility to IDV, LPV, and SQV and possibly other PIs. F53Y is a rare treatment-associated variant. 54 V I54V contributes resistance to each of the PIs except possibly DRV when present with other mutations. 54 M I54M occurs in patients receiving FPV, LPV, and DRV and reduces susceptibility to these drugs and to ATV and NFV. 54 L I54L occurs in patients receiving FPV, LPV, and DRV and reduces susceptibility to these drugs and to NFV and possibly ATV. It is associated with increased susceptibility to TPV. 54 ATS I54T/A/S are PI-related mutations typically observed in heavily treated persons and like I54V and I54M/L are likely to reduce susceptibility to most PIs. 58 E Q58E is a nonpolymorphic mutation that occurs more commonly in treated patients. It has been associated with decreased virological response to TPV but probably is associated with resistance to multiple PIs. 60 E D60E is a polymorphic mutation that is slightly more common in viruses from PI-treated compared with untreated persons. It was weakly associated with a decreased virologic response to ATV in one of three retrospective analyses. 62 V I62V is a highly polymorphic mutation that is more common in PI-treated compared with untreated persons. It was weakly associated with a decreased virologic response to ATV in one of three retrospective analyses. 63 P L63P is a common polymorphism that becomes even more common in persons receiving PIs. 69 K H69K is a highly polymorphic residue that was weakly associated with a decreased virologic response to TPV in the RESIST trials. 71 VTIL A71T/V are polymorphisms that occur in 1-2% of untreated persons but which become much more frequent in persons receiving PIs. A71I is an uncommon mutation that appears to occur only with PI therapy; its significance is not known. 73 STCA G73S/T/C/A are selected by and appear to be associated with decreased susceptibility to most, if not all, PIs. 74 SP T74S is associated with reduced NFV susceptibility. It occasionally occurs in untreated persons. T74P is a nonpolymorphic mutation that occurs more commonly in heavily treated patients. It has been associated with decreased virological response to TPV but probably is associated with resistance to multiple PIs. 74 A T74A is a polymorphic mutation more common in viruses from persons receiving PIs (particularly NFV and SQV) than in PI-naive persons. 76 V L76V reduces susceptibility to FPV, IDV, LPV, and DRV and increases susceptibility to SQV and ATV. 77 I V77I is a common polymorphism that is associated with NFV therapy. 82 A V82A reduces susceptibility to IDV and LPV. With other mutations it is associated with reduced susceptibility to NFV, ATV, SQV, FPV, and TPV. 82 T V82T reduces susceptibility to IDV, LPV, and TPV. With other mutations it is associated with reduced susceptibility to NFV, ATV, FPV, and SQV. 82 F V82F reduces susceptibility to IDV, LPV, FPV, and DRV. With other mutations it is associated with reduced susceptibility to NFV, ATV, SQV, and TPV. 82 S V82S probably has a similar effect to V82T which reduces susceptibility to IDV, LPV, and TPV and with other mutations is associated with reduced susceptibility to NFV, ATV, FPV, and SQV. 82 M V82M has been shown to cause IDV resistance in subtype G viruses in which it is a common mutation. Its effect on other PIs has not been studied. 82 I V82I is a polymorphism that is common in some non-B subtypes; it has little if any effect on PI susceptibility. 82 L V82L is a rare TPV-selected mutation. Its effect on other PIs has not been characterized. 82 C V82C is a rare mutation that occurs primarily in protease genes containing multiple other PI-resistance mutations. 83 D N83D is a nonpolymorphic mutation that occurs more commonly in heavily treated patients. It has been associated with decreased virological response to TPV but probably is associated with resistance to multiple PIs. 84 V I84V causes intermediate/high-level resistance to ATV, FPV, IDV, NFV, SQV, and TPV, and low-level intermediate resistance to LPV and DRV. 84 AC I84A/C are rare mutations that like I84V appear to reduce susceptibility to each of the PIs. 85 V I85V is a nonpolymorphic PI-selected mutation. It was weakly associated with a decreased virologic response to ATV in one of three retrospective analyses. 88 S N88S causes high-level resistance to NFV and ATV and low-level resistance to IDV; it increases susceptibility to FPV. 88 T N88T has not been studied but is likely to be similar to N88S which causes high-level resistance to NFV and ATV, low-level resistance to IDV, and increased susceptibility to FPV. 88 G N88G has not been studied but is likely to be similar to N88S which causes high-level resistance to NFV and ATV, low-level resistance to IDV, and increased susceptibility to FPV. 89 V L89V is an uncommon nonpolymorphic PI-selected accessory mutation. It is one of the 11 mutations associated with decreased response to DRV in the POWER trials. 90 M L90M causes resistance to NFV, SQV, ATV, and IDV. When present with other mutations it also compromises the activity of FPV, LPV, and TPV. Its effect on DRV is not known. 93 L I93L is a common polymorphism that becomes even more common in persons receiving PIs. 93 M I93M is a rare PI-associated mutation; its effect on PI susceptibility is not known.